1. Scrip
  3. >>Clinical Trials

SELECTION Positive For Gilead/Galapagos’s Filgotinib In UC But Will It Be Enough To Compete?

Ulcerative Colitis Market Is Crowded

 
• By Alexandra Shimmings

Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.    

Human colon
• Source: Shutterstock

While Gilead Sciences Inc. and Galapagos NVawait the first approval decisions for their JAK1 inhibitor filgotinib for rheumatoid arthritis, top-line data from the SELECTION study show it has potential in another of its indications, ulcerative colitis.

What remains to be determined, however, is how well the product will be able to compete in this market against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D